The Research Value of Multi-omics and Multi-modal Information in the Diagnosis and Treatment of Urinary System Tumors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06490211

Enrollment

100

Registered

2024-07-08

Start date

2023-11-20

Completion date

2026-11-20

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary System Carcinoma

Brief summary

Obtain puncture or surgically removed tumor tissue samples from patients with urinary tract tumors and perform RNA-sequencing, Single-cell RNA-sequence, Spatial Transcriptomics, Proteomics, and Intratumoral Microbiome.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients were treated for bladder cancer, kidney cancer, and prostate cancer in Wuhan Union Hospital from January 2024 to January 2026; 2. Aged \> 18 years old; 3. Urinalysis, urine exfoliated cells, ultrasound, CT, and MR examinations indicated the above tumors; 4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

Exclusion criteria

1. Poor image quality; 2. Incomplete clinical data or loss of follow-up; 3. Presence of another primary malignant tumor other than urinary tract tumor; 4. Unclear pathological diagnosis

Design outcomes

Primary

Measure	Time frame
progression-free survival	2 years

Countries

China

Contacts

Primary ContactLian Yang

yanglian@hust.edu.cn18986273791

Outcome results